| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT03975829 Pediatric Long-Term Follow-up and Rollover Study |
overall status: "Recruiting" → "Active Not Recruiting" |
| 2026-06-10 | NCT07468071 Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit… |
Recruitment opened |
| 2026-05-29 | NCT02224781 Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and… |
Trial sites reduced: 843 -> 840 locations |
| 2026-05-29 | NCT02224781 Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and… |
date change Completion pushed: 2026-09-11 -> 2026-12-19 |
| 2026-05-20 | NCT04439292 Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF… |
Enrollment increased: 35 -> 44 participants |
| 2026-05-16 | NCT06475989 Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer |
Trial sites expanded: 112 -> 301 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT03340506 | Dabrafenib and/or Trametinib Rollover Study | Melanoma | Recruiting |
| NCT03975829 | Pediatric Long-Term Follow-up and Rollover Study | Diffuse Astrocytoma | Active, Not Recruiting |
| Phase 3 | |||
| NCT06475989 | Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer | Refractory Differentiated Thyroid Gland Carcinoma | Recruiting |
| NCT06346067 | A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With… | Advanced or Metastatic NRAS-mutant Melanoma | Active, Not Recruiting |
| NCT02224781 | Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and… | Clinical Stage III Cutaneous Melanoma AJCC v8 | Active, Not Recruiting |
| NCT04940052 | Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously… | Differentiated Thyroid Cancer (DTC) | Active, Not Recruiting |
| Phase 2/3 | |||
| NCT07440290 | DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult… | Haematological Malignancy | Not Yet Recruiting |
| Phase 2 | |||
| NCT07477457 | A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard… | Osteosarcoma | Recruiting |
| NCT04943224 | Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients | Histiocytosis | Recruiting |
| NCT06582745 | Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib | Langerhans Cell Histiocytosis | Recruiting |
| NCT04116541 | A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular… | Malignant Solid Tumor | Recruiting |
| NCT03899155 | Pan Tumor Rollover Study | Cancer | Recruiting |
| NCT07110246 | Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas | BRAF V600 Mutation | Recruiting |
| NCT03087071 | Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal… | EGFR NP_005219.2:p.S492R | Active, Not Recruiting |
| NCT02231775 | Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C… | Stage IIIB Cutaneous Melanoma AJCC v7 | Active, Not Recruiting |
| NCT04675710 | Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of… | Thyroid Gland Anaplastic Carcinoma | Active, Not Recruiting |
| NCT04417621 | Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated… | Melanoma | Active, Not Recruiting |
| NCT01979523 | Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma | Recurrent Uveal Melanoma | Active, Not Recruiting |
| NCT02152995 | Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or… | Metastatic Thyroid Gland Carcinoma | Active, Not Recruiting |
| NCT04439318 | Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes… | Advanced Lymphoma | Active, Not Recruiting |
| NCT04439357 | Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11… | Advanced Lymphoma | Active, Not Recruiting |
| NCT03149029 | Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma | Metastatic Melanoma | Active, Not Recruiting |
| NCT03363217 | Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of… | Low-grade Glioma | Active, Not Recruiting |
| NCT07549646 | 24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs | Ras/MAPK Pathway Vascular Anomalies | Active, Not Recruiting |
| NCT04439279 | Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes… | Advanced Lymphoma | Active, Not Recruiting |